Drugmakers Still Pay to Keep Generics Off Market, FTC Says

Brand-name drugmakers are continuing an “anticompetitive” trend of paying generic-drug manufacturers to delay introducing their lower-cost products, according to a Federal Trade Commission report. … Read More